Tuesday, January 6, 2026 1/6/2026

Targeting tumor cell mitochondria for the prevention and treatment of lung cancer

Award Number: R01CA285608
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/01/2025
PERIOD OF PERFORMANCE END DATE: 12/31/2029

Group Awards By:

View Award Description

Targeting tumor cell mitochondria for the prevention and treatment of lung cancer - Lung cancer is the leading cause of cancer-related mortality in the United States and adenocarcinoma (ADC) is the most common histological type of lung cancer. Kras mutations occur in 20–40% of lung ADCs and, among Kras-mutant lung tumors (K tumors), concurrent mutations of Kras and the tumor suppressor gene LKB1 (KL tumors) ranged from 8% to 31%. Loss of function of LKB1 can also be induced through DNA methylation and phosphorylation of wild-type LKB1. Lung tumors induced by tobacco smoke and tobacco smoke carcinogens exhibit Kras mutation and methylation/phosphorylation of LKB1, thereby sharing several features with KL tumors. Tumors with alterations in both Kras and LKB1 are highly aggressive and not amenable to existing therapies, including immunotherapy. Therefore, the long-term goal of this application is to develop novel, safe and effective agents for the prevention and therapy of KL tumors. Since KL lung tumors are characterized by high levels of metabolic and oxidative stress, further enhancement oxidative stress through small molecules may preferentially induce the death of cancer cells due to their inherent vulnerability to oxidative stress. We hypothesize that mitomet, a mitochondria-targeted metformin analog, which selectively accumulates in the mitochondria of tumor cells and induces energetic and redox stress prevents malignant progression of lung tumors with co-occurring Kras and LKB1 alterations and sensitize these tumors to immune checkpoint blockade, in KL tumors. Our hypothesis is supported by extensive preliminary data. On the basis of these preliminary findings, we propose the following Specific Aims. Specific Aim 1: Assess the safety of mitomet and determine its efficacy to suppress malignant progression of NNK-induced lung tumors in mice. Specific Aim 2: Determine the efficacy of mitomet to suppress malignant progression of mouse lung tumors with co-occurring Kras and LKB1 mutations and to modulate the tumor immune microenvironment and thereby reverse the resistance of KL tumors to immunotherapy. Specific Aim 3: Compare the tumor propagating potential of CD44+ CD133+ and CD44—CD133— fractions of mouse KL tumor cells and assess if mitomet and/or immunotherapy suppress the tumor propagating capacity of CD44+ CD133+ mouse KL tumor cells. Tumor cells for these studies will be obtained from Aim 2. This proposal will elucidate whether Kras mutation and LKB1 loss-associated energetic and redox stress renders KL tumor cells differentially sensitive to mitomet. The results of these studies will lay the groundwork for future clinical trials of mitomet for the prevention and therapy of human KL lung cancer.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $317,048 )
2026	2026	REGENTS OF THE UNIVERSITY OF MINNESOTA	2221 UNIVERSITY AVE SE STE 100	MINNEAPOLIS	MN	55414	HENNEPIN	USA	Cancer Cause and Prevention Research	000	2	12/23/2025	NON-COMPETING CONTINUATION	$317,048
														Subtotal = $317,048

Issue Date FY: 2025 ( Subtotal = $352,275 )
2025	2025	REGENTS OF THE UNIVERSITY OF MINNESOTA	200 OAK ST SE	MINNEAPOLIS	MN	55455	HENNEPIN	USA	Cancer Cause and Prevention Research	000	1	12/27/2024	NEW	$352,275
														Subtotal = $352,275

Grand Total All Awards = $669,323

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeting tumor cell mitochondria for the prevention and treatment of lung cancer

Award Number: R01CA285608

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/01/2025

PERIOD OF PERFORMANCE END DATE: 12/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer